DK0556239T3 - Aerosol indeholdende medikamenter - Google Patents

Aerosol indeholdende medikamenter

Info

Publication number
DK0556239T3
DK0556239T3 DK91919478.7T DK91919478T DK0556239T3 DK 0556239 T3 DK0556239 T3 DK 0556239T3 DK 91919478 T DK91919478 T DK 91919478T DK 0556239 T3 DK0556239 T3 DK 0556239T3
Authority
DK
Denmark
Prior art keywords
amino
containing drugs
aerosol containing
benzenemethanol
salmeterol
Prior art date
Application number
DK91919478.7T
Other languages
Danish (da)
English (en)
Inventor
Anthony James Taylor
Patricia Kwong Phieu Burnell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0556239T3 publication Critical patent/DK0556239T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK91919478.7T 1990-11-09 1991-11-07 Aerosol indeholdende medikamenter DK0556239T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909024366A GB9024366D0 (en) 1990-11-09 1990-11-09 Medicaments

Publications (1)

Publication Number Publication Date
DK0556239T3 true DK0556239T3 (da) 1995-11-06

Family

ID=10685110

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91919478.7T DK0556239T3 (da) 1990-11-09 1991-11-07 Aerosol indeholdende medikamenter

Country Status (11)

Country Link
EP (1) EP0556239B1 (ja)
JP (1) JP3468767B2 (ja)
AT (1) ATE127012T1 (ja)
AU (1) AU653369B2 (ja)
CA (1) CA2094727C (ja)
DE (1) DE69112635T2 (ja)
DK (1) DK0556239T3 (ja)
ES (1) ES2078550T3 (ja)
GB (1) GB9024366D0 (ja)
GR (1) GR3018171T3 (ja)
WO (1) WO1992008447A1 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104650D0 (en) * 1991-03-05 1991-04-17 Glaxo Group Ltd Medicaments
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
WO1993011744A1 (en) * 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5593661A (en) * 1993-03-29 1997-01-14 Henry; Richard A. Lidocaine aerosol anaesthetic
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP0731688B1 (en) * 1993-12-02 2003-03-05 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
US5711934A (en) * 1994-04-11 1998-01-27 Abbott Laboratories Process for the continuous milling of aerosol pharmaceutical formulations in aerosol propellants
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000061108A1 (en) * 1999-04-14 2000-10-19 Glaxo Group Limited Pharmaceutical aerosol formulation
ATE446085T1 (de) 2000-11-30 2009-11-15 Vectura Ltd Partikel zur verwendung in einer pharmazeutischen zusammensetzung
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0130703D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Particles
WO2004103348A2 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
BR112014008114B1 (pt) 2011-10-11 2022-07-26 Chiesi Farmaceutici S.P.A. Micropartículas cristalinas, formulação farmacêutica, inalador dosimetrado pressurizado, formulação farmacêutica, processo para preparar microparticulas cristalinas e uso de micropartículas cristalinas
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
AU2017328910B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen

Also Published As

Publication number Publication date
AU653369B2 (en) 1994-09-29
CA2094727C (en) 2002-01-15
GB9024366D0 (en) 1991-01-02
GR3018171T3 (en) 1996-02-29
CA2094727A1 (en) 1992-05-10
EP0556239B1 (en) 1995-08-30
JPH06501693A (ja) 1994-02-24
AU8862991A (en) 1992-06-11
DE69112635D1 (de) 1995-10-05
DE69112635T2 (de) 1996-02-08
WO1992008447A1 (en) 1992-05-29
EP0556239A1 (en) 1993-08-25
JP3468767B2 (ja) 2003-11-17
ATE127012T1 (de) 1995-09-15
ES2078550T3 (es) 1995-12-16

Similar Documents

Publication Publication Date Title
DK0556239T3 (da) Aerosol indeholdende medikamenter
ATE127013T1 (de) Aerosolzusammensetzungen.
ES2151476T3 (es) Formulaciones de farmacos en aerosol.
ES2189410T3 (es) Formulacion farmaceutica en aerosol.
NO972781L (no) Aerosolformuleringer av peptider og proteiner
FI90014B (fi) Foerfarande foer loesning av ett laekemedel som loeser sig daoligt i klorfluorkolvaete-aerosoldrivmedel
AR002009A1 (es) Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
FI963424A0 (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
ZA200004757B (en) Pharmaceutical formulation comprising A 2-[[(2-pyridinyl)methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation.
CA2353847A1 (en) Pulmonary drug delivery
DE69631881D1 (de) Pulmonale verabreichung von medikamenten in aerosolform
MD970134A (en) A pharmaceutical aerosol formulation, process for preparation thereof, method of treatment of respiratory affections, surfactant for such formulations and process for obtaining thereof A pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon of hydrogen-containing chlorofluorocarbon propellant and a surfactant of general formula (I) <CHFORM> wherein n is an integer of 1 to 18m is an integer of 0 to 17; and R1, R2 and R3 are each independently a hydrogen atom or a C1-4alkyl group. Claims: 20
NO305028B1 (no) AnalogifremgangsmÕte for fremstilling av terapeutisk aktive pyridin N-oxydderivater av diarylmethylpiperidiner eller piperaziner
NZ240237A (en) An aerosol formulation (free of surfactant) for treatment of asthma comprising: a hydrofluorocarbon propellant, ethanol, and beclomethasone 17,21 dipropionate; preparation thereof
CA2402300A1 (en) Fluorocarbon aerosol medicaments
NO971898L (no) Farmasöytiske preparater
ATE233084T1 (de) Pharmazeutische aerosolformulierung
ATE85757T1 (de) Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.
IE900391L (en) N-(3-pyridyl) guanidine derivative
ES2077243T3 (es) Composiciones farmaceuticas con liberacion controlada y contorno lateral revestido.
SE9101687D0 (sv) Dikloranilinfoerening
NO971519L (no) Fremgangsmåte for fremstilling av antigenisk forsterkede enterier og vaksiner inneholdende disse
IL152005A0 (en) Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and and pharmaceutical preparations containing them
ATE286716T1 (de) Pharmazeutische formulierungen enthaltend salmeterol
SE9702545L (sv) Absorberande alster och metod att tillverka detsamma